DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that it is participating in San Diego nonprofit Connect’s inaugural Five.Ten.Thirty event. Taking place on April 28, 2022 at Petco Park, the gathering is a celebration of San Diego’s first annual ‘Innovation Day,’ recently declared by Mayor Todd Gloria.

The event will bring together the city’s most innovative business leaders and companies working towards a more robust and inclusive economy across the region. Five.Ten.Thirty is the largest innovation celebration in San Diego history, with more than 100 local life science and technology companies on display, showcasing their cutting-edge technologies and business solutions.

DermTech will showcase its translational medicine service offering, DermTech Stratum™, which provides research and development partners with the opportunity to non-invasively collect skin samples to identify biomarkers of disease and subgroups of disease, stratify patients based on genomic and proteomic profiles, enrich for responders in a population, and predict and track responses to therapeutic intervention.

Recently, DermTech Stratum added a new research use test to differentiate two chronic inflammatory skin diseases, atopic dermatitis (AD) and psoriasis (PS). Atopic dermatitis and psoriasis are the two most common inflammatory diseases globally, affecting approximately 10% and 3% of the U.S. population respectively. The new AD vs. PS test will allow researchers to differentiate the inflammatory signatures of atopic dermatitis from psoriasis and others in potential clinical trial participants. Additional research use assays are currently in development for other inflammatory skin diseases and skin cancers.

“We are excited to join some of the San Diego region’s most innovative companies and creative minds to celebrate Innovation Day,” said Michael Howell, Ph.D., chief scientific officer of DermTech. “San Diego is a growing leader in biotechnology and life sciences; we look forward to showcasing the advancements that DermTech has made in the precision and personalized dermatology category.”

Five.Ten.Thirty is expected to draw thousands of attendees, including key leaders, company teams, local government agencies, angel investors, venture-backed CEOs and more.

To learn more about Five.Ten.Thirty, visit www.connect.org. For additional information about DermTech, visit www.dermtech.com.

About DermTech:

DermTech is a leading genomics company in dermatology and is creating a new category of medicine, precision dermatology, enabled by its non-invasive skin genomics platform. DermTech’s mission is to improve the lives of millions by providing non-invasive precision dermatology solutions that enable individualized care. DermTech provides genomic analysis of skin samples collected non-invasively using our Smart Stickers^TM. DermTech markets and develops products that facilitate the early detection of skin cancers and is developing products that assess inflammatory diseases and customize drug treatments. For additional information, please visit DermTech.com.

Forward-Looking Statements:

This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. The expectations, estimates, and projections of DermTech may differ from its actual results and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, expectations and evaluations with respect to: the performance, patient benefits, benefits to research partners and collaborators, cost-effectiveness, commercialization and adoption of DermTech’s products and services and the market opportunity for these products, and DermTech’s ability to expand its product and service offerings and develop pipeline products. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the control of DermTech and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the outcome of any legal proceedings that may be instituted against DermTech; (2) DermTech’s ability to obtain additional funding to develop and market its products and services; (3) the existence of favorable or unfavorable clinical guidelines for DermTech’s tests; (4) the reimbursement of DermTech’s tests by Medicare and private payors; (5) the ability of patients or healthcare providers to obtain coverage of or sufficient reimbursement for DermTech’s products; (6) DermTech’s ability to grow, manage growth and retain its key employees; (7) changes in applicable laws or regulations; (8) the market adoption and demand for DermTech’s products and services together with the possibility that DermTech may be adversely affected by other economic, business, and/or competitive factors; and (9) other risks and uncertainties included in (x) the “Risk Factors” section of the most recent Annual Report on Form 10-K filed by DermTech with the Securities and Exchange Commission (the “SEC”), and (y) other documents filed or to be filed by DermTech with the SEC, including subsequently filed reports. DermTech cautions that the foregoing list of factors is not exclusive. You should not place undue reliance upon any forward-looking statements, which speak only as of the date made. DermTech does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220425005812/en/